Internal Medicine, Medical Oncology · Webster, TX
NPI
1639360829
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
5
Medicare group memberships
Hospitals
3
Hospital affiliations
905 W Medical Center Blvd Ste 304
Webster, TX, 77598
Phone (281) 724-8335
Groups this clinician bills Medicare through
Medicare paid, 2024
$315K
16,820 services
Medicare patients, 2024
425
Average age 75
Drug cost, 2024
$4.2M
1,832 prescriptions
Company payments, 2025
$9,083
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John G Knecht III was code 99232 (hospital e&m - subsequent), 542 times for 150 patients. In total John G Knecht III billed 16,820 services in 54 codes, and Medicare paid $315K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 542 | 150 | $61.70 | $33K |
| 99214 Office E&M - Established | Office | 284 | 167 | $93.21 | $26K |
| 99233 Hospital E&M - Subsequent | Facility | 215 | 121 | $91.74 | $20K |
| 99222 Hospital E&M - Initial | Facility | 91 | 85 | $102.60 | $9,337 |
| 99223 Hospital E&M - Initial | Facility | 82 | 79 | $136.76 | $11K |
| 99215 Office E&M - Established | Office | 80 | 25 | $132.18 | $11K |
| 99204 Office E&M - New | Office | 78 | 78 | $129.42 | $10K |
| 96365 Intravenous Infusion, Hydration | Office | 38 | 21 | $48.28 | $1,835 |
| 99205 Office E&M - New | Office | 11 | 11 | $152.46 | $1,677 |
By year: 2022 $385K for 26,489 services; 2023 $395K for 19,410 services; 2024 $315K for 16,820 services.
Medicare prescription drug claims, 2024
In 2024, the drug John G Knecht III prescribed most often to Medicare patients was Eliquis (Apixaban), with 127 prescriptions and refills. In total John G Knecht III wrote 1,832 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 127 | 172 | 30 | $98K |
| Anastrozole Generic | 110 | 247 | 31 | $1,622 |
| Xarelto Rivaroxaban | 57 | 104 | 17 | $59K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 45 | 45 | 13 | $2,448 |
| Jakafi Ruxolitinib Phosphate | 43 | 43 | Under 11 | $752K |
| Procrit Epoetin Alfa | 43 | 43 | Under 11 | $14K |
| Metformin Hcl Generic | 35 | 51 | Under 11 | $153 |
| Furosemide Generic | 32 | 49 | 13 | $114 |
| Keytruda Pembrolizumab | 29 | 29 | Under 11 | $366K |
| Pantoprazole Sodium Generic | 27 | 31 | Under 11 | $84 |
| Gabapentin Generic | 27 | 29 | Under 11 | $284 |
| Tamsulosin Hcl Generic | 27 | 53 | Under 11 | $477 |
| Imatinib Mesylate Generic | 27 | 27 | Under 11 | $19K |
| Levothyroxine Sodium Generic | 26 | 49 | 12 | $260 |
| Fluorouracil Generic | 25 | 25 | Under 11 | $1,058 |
Brand drugs: 634 claims; generic drugs: 1,198 claims; opioid claims: 80.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John G Knecht III $9,083 ($9,083 in general payments such as food, travel and fees) from 42 companies. The largest payer was Regeneron Pharmaceuticals, Inc. with $2,588.
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. REGN | 3 | $2,588 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $1,870 |
| GlaxoSmithKline, LLC. GSK | 10 | $439 |
| Astellas Pharma US Inc 4503.T | 9 | $348 |
| Pfizer Inc. PFE | 10 | $303 |
| Daiichi Sankyo Inc. 4568.T | 5 | $275 |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $265 |
| Janssen Biotech, Inc. JNJ | 4 | $257 |
| Merck Sharp & Dohme LLC MRK | 10 | $250 |
| Incyte Corporation INCY | 6 | $241 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.